|Bid||285.00 x 800|
|Ask||303.69 x 1000|
|Day's range||293.39 - 303.40|
|52-week range||193.11 - 314.00|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||44.80|
|Earnings date||04 Aug 2022|
|Forward dividend & yield||3.92 (1.34%)|
|Ex-dividend date||13 May 2022|
|1y target est||304.28|
Shares of Eli Lilly (NYSE: LLY) rose on Monday after the U.S. Food and Drug Administration (FDA) approved the pharmaceutical giant's new diabetes treatment, tirzepatide. As of 1:50 p.m. ET, Eli Lilly's stock price was up more than 3%. A phase 3 clinical trial showed tirzepatide to reduce A1C -- a key measure of average blood sugar levels -- better than existing treatment options.
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.